I'm LongbridgeAI, I can summarize articles.Purple Biotech rose 3.25% in after-hours trading; Novo Nordisk fell 0.09% in after-hours trading, with a transaction volume of USD 2.24 million; Eli Lilly rose 0.03% in after-hours trading, with a transaction volume of USD 2.05 million; Johnson & Johnson fell 0.03% in after-hours trading, with a transaction volume of USD 537,700
U.S. Stock Night Market Movements
Purple Biotech rose 3.25% in the night market, with no significant news recently. Trading is active, and capital flows are evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation.
Stocks with High Trading Volume in the Industry
Novo Nordisk fell 0.09% in the night market. Based on recent key news:
-
On June 11, Novo Nordisk reported unauthorized access to its internal IT systems, and certain systems have been taken offline for security reasons. This incident may affect investor confidence and lead to stock price fluctuations. Source: Reuters
-
On June 9, analysts pointed out that the efficacy of Novo Nordisk's Wegovy has diminished, with about one-quarter to one-third of patients no longer losing weight, which may affect market confidence in the drug. Source: MarketWatch
-
On June 9, Goldman Sachs reported that competition in the GLP-1 drug market is intensifying, with increased pricing pressure, posing a risk of market share erosion for Novo Nordisk. Source: Goldman Sachs
Eli Lilly rose 0.03% in the night market. Based on recent key news:
-
On June 9, Eli Lilly announced the results of its Phase III clinical trial for the new generation weight loss drug Retatrutide, showing excellent weight loss effects, causing the stock price to rise 1.6% and return to the trillion-dollar market cap club. Source: MoneyDJ News
-
On June 9, Eli Lilly reached a cooperation agreement with Swedish pharmaceutical company AlzeCure Pharma regarding global rights to Alzheimer's research candidates, with a total transaction value exceeding $1 billion, driving the stock price up. Source: Investing.com
-
On June 10, Jefferies raised Eli Lilly's target price from $1,330 to $1,350, maintaining a "Buy" rating, further boosting market confidence. Source: Gelonghui
Johnson & Johnson fell 0.03% in the night market. Based on recent key news:
-
On June 11, Johnson & Johnson announced the full launch of its TECNIS PureSee intraocular lens in the U.S. The launch of this product enhances the company's competitiveness in the ophthalmic surgery market, which may positively impact the stock price. Source: Zhitong Finance
-
On June 10, Johnson & Johnson's Shockwave Medical filed a patent infringement lawsuit in Europe involving core technologies. This may increase legal costs and uncertainty, putting pressure on the stock price. Source: Wall Street Insight
-
On June 9, Johnson & Johnson announced its 64th consecutive dividend increase, demonstrating the company's stable cash flow and shareholder return capability, which may support the stock price. Source: MarketWatch
Innovation in the pharmaceutical industry drives growth, with attention to regulatory risks